Frans M J Debruyne

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Antonio Alcaraz, Jens Rassweiler, Christian Gratzke, 2017, The Lancet. Oncology.